About Us

DNA was founded in 1992, and for over 30 years we have served the pharmaceutical industry in the United States, Latin America and the Caribbean.

In 2012 we acquired a research, manufacturing and distribution company in Cape Town, South Africa and a new entity was formed, DNA BIOPHARM which now manufactures 40 natural products. 

Now DNA brings our first product from South Africa to America... NEURO-FAST. 

NEURO-FAST is an all natural product designed to help patients with Neuropathy.  No side effects have been reported with NEURO-FAST.  As a natural product NEURO-FAST. utilizes 8 natural compounds that work in harmony to help patients deal with the pain and discomfort of Neuropathy without having to deal with the undesired side effects.

NEURO-FAST has been in the market for over 10 years and thousands of patients have found the relief the are looking for in their fight against Neuropathy.  Patients begin feeling the comfort by the second month of treatment, that is why we are offering a BUY 2 get 1 FREE offer, this way every patient that buys the starting treatment and feel the positive effects of NEURO-FAST.

NEURO-FAST is manufactured in America complying with and following all the State and Federal regulations in a GMP approved facility.

                                                                                    "HARNESS THE POWER OF NATURE"

in 2027 we will also bring to the market XERIODERM, a natural treatment to combat the effects of Psoriasis.  After 15 years in the market XERIODERM has proven to be an excellent weapon in the fight against Psoriasis and no side effects have ever been reported with its use.

Without causing any side effects, XERIODERM is effective with a treatment that takes between 3 and 4 months, depending on the severity of Psoriatic episode the patient is suffering at the time of treatment with long lasting effects. 

We also have partnered with Advin Biotech Inc. to distribute in Latin America non invasive drug tests QuikTox™  Ultra Cup and QuikTox™  Oral Screen. 

QuikTox™   Ultra Cup The QuikTox™ Drug Test Cup is an all-in-one, on-site urine drug screening device that simplifies the collection process and tests for up to 22 drugs.

QuikTox™  Oral Screen is a  new innovative Oral Fluid Test that delivers ultra-fast testing with a noninvasive sampling techniques that is easy for the user to collect and handle. This Cassette is highly effective and provide exceptional accuracy and reliability, specifically detecting parent THC and other common drugs.

Our drug screening products test for the most commonly abused drugs, in various combinations. All of our CLIA-waived and FDA-cleared tests are customizable to your organization’s selected cutoff levels. We’re constantly updating our list with new drugs to stay current with the market.

ABOUT NEUROPATHY

Neuropathy Facts and Statistics: How Common Is It Really?*

*https://neuropathyresource.com/

How Many People Have Peripheral Neuropathy?

United States Prevalence

The most commonly cited figure is that more than 20 million Americans have some form of peripheral neuropathy. However, the National Institute of Neurological Disorders and Stroke (NINDS) notes that this is almost certainly an undercount — many people with neuropathy symptoms are never formally tested, and current diagnostic tests don’t detect all forms of the condition.

More recent estimates place the actual figure at 20–30 million Americans, with many researchers believing the true number is even higher when accounting for undiagnosed cases.

Global Prevalence

Worldwide, estimates suggest approximately 190 million people have some form of peripheral neuropathy — making it one of the most common neurological conditions on the planet. Given global diabetes rates and an aging population, this number continues to rise.

Prevalence Increases Dramatically With Age

Neuropathy becomes significantly more common as people age. General population prevalence estimates range from about 2-3% in the general adult population to 8% in those over 55. But in elderly populations, the numbers are even more striking.

A 2025 study using the Michigan Neuropathy Screening Instrument found that among very old adults, the prevalence of detectable peripheral neuropathy was 62.4% — nearly two-thirds of the elderly population studied. Even among those without diabetes, the rate was 60.2%.

Key Takeaway

20–30 million Americans live with peripheral neuropathy — more than Parkinson’s disease, MS, and ALS combined. Yet it receives a fraction of the research funding and public awareness of those conditions. You are not alone.

Population Group                                                    Estimated Prevalence              

General adult population                            ~2–3%

Adults over age 55                                        ~8%

Adults with diabetes                                     ~50–60%

People with pre-diabetes                            ~11–25% (varies by study)

Cancer patients on chemo                         ~30–40%

People with HIV/AIDS                                     ~30–35%

Very old adults (80+)                                    ~62% (2025 study)

                        U.S. Total Population (Estimated)               20-30 Million People.

Neuropathy by Cause: A Statistical Breakdown

One of the most important things to understand about neuropathy statistics is that “peripheral neuropathy” is an umbrella term covering many different conditions with different underlying causes. Here’s how the numbers break down by cause:

Diabetic Neuropathy — The Leading Cause

Diabetes is the single most common cause of peripheral neuropathy in the United States. About 60–70% of people with diabetes develop some form of nerve damage over time. This translates to an estimated 13.2 million Americans with diabetic peripheral neuropathy (DPN) specifically.

The economic impact of diabetic neuropathy alone is enormous. The estimated annual cost of treating diabetes-related chronic complications — including DPN — is $58 billion in the United States. A separate 2025 analysis estimated the annual cost burden of diabetic peripheral neuropathy at tens of billions of dollars when accounting for direct medical costs, lost productivity, and quality-of-life impacts.

Idiopathic Neuropathy — More Common Than You Think

The second most common diagnosis is idiopathic neuropathy — neuropathy with no identifiable cause. Estimates suggest that 30–40% of all neuropathy cases fall into this category, though some research puts the figure even higher. Many of these cases likely have underlying causes that current testing hasn’t identified or that remain poorly understood.

                          20–30M                                                  190M                                                           62%

 Americans with neuropathy             People worldwide     Prevalence in adults 80+ (2025 study)

Chemotherapy-Induced Peripheral Neuropathy (CIPN)

30–40% of all cancer patients receiving chemotherapy develop peripheral neuropathy as a side effect. Certain chemotherapy agents — platinum drugs (cisplatin, oxaliplatin), taxanes (paclitaxel, docetaxel), and vinca alkaloids — carry particularly high neuropathy risk. CIPN is one of the leading reasons patients reduce chemotherapy doses or discontinue treatment entirely.

Given that roughly 18.1 million Americans have cancer, and many are receiving chemotherapy at any given time, the number of CIPN cases is substantial. For a full overview, see our article on chemotherapy-induced neuropathy.

Alcoholic Neuropathy

Alcohol is a significant but often underrecognized cause of neuropathy. Studies suggest that 25–66% of people with chronic alcoholism develop some degree of peripheral neuropathy, with estimates varying widely based on how neuropathy is defined and the population studied. This makes it one of the more common causes, though it often goes undiagnosed because people with alcohol use disorders may not seek medical care for neuropathy symptoms.

Cause Category                             Approximate % of                            Notes

                                                                   Neuropathy Cases

Diabetic neuropathy               ~30–35% of all cases.                   Leading identifiable cause

Idiopathic 

(unknown cause)                    ~30–40%                                         Often older adults

Chemotherapy (CIPN).            ~10–15%                                          Among cancer patients: 30–40%

Alcohol-related                         ~10–15%                                          Highly under-diagnosed

Hereditary            

(CMT and others)                        ~5–8%                                          Charcot-Marie-Tooth most common

Autoimmune 

(GBS, CIDP, lupus)                            ~5%                                          Treatable if identified early

Vitamin deficiency 

(B12, B1, etc.)                                      ~5%                                           Fully preventable/reversible

HIV/AIDS-related                         ~3–5%                                          30–35% of HIV+ patients

Medication-induced 

(non-chemo)                               ~3–4%                                          See medications that cause neuropathy

Thyroid disease                            ~2–3%                                          Hypothyroidism most common

Note: Percentages are approximate and overlap exists — many patients have multiple contributing factors.

Neuropathy Demographics: Who Is Most Affected?

Age

Age is the single strongest risk factor for neuropathy. Prevalence roughly doubles or triples in each successive age decade after 55. Most people diagnosed with neuropathy are over 60, though it certainly affects younger people — especially those with diabetes, hereditary neuropathy, autoimmune conditions, or cancer.

Research Says 60–70% of people with diabetes develop some form of nerve damage over time. An estimated 13.2 million Americans have diabetic peripheral neuropathy specifically. The annual cost of diabetes-related chronic complications including DPN is estimated at $58 billion in the U.S. alone. (Sources: ADA, NINDS, peer-reviewed epidemiological studies)

Diabetic Neuropathy — The Leading Cause

Diabetes is the single most common cause of peripheral neuropathy in the United States. About 60–70% of people with diabetes develop some form of nerve damage over time. This translates to an estimated 13.2 million Americans with diabetic peripheral neuropathy (DPN) specifically.

                           20–30M                                            190M                                                       62%

   Americans with neuropathy     People worldwide      Prevalence in adults 80+ (2025 study)

Idiopathic Neuropathy — More Common Than You Think

The second most common diagnosis is idiopathic neuropathy — neuropathy with no identifiable cause. Estimates suggest that 30–40% of all neuropathy cases fall into this category, though some research puts the figure even higher. Many of these cases likely have underlying causes that current testing hasn’t identified or that remain poorly understood.

Studies consistently show that neuropathy substantially reduces quality of life. People with neuropathy report significantly worse scores on standardized quality-of-life measures compared to matched controls, with impacts on physical function, sleep, mental health, social participation, and independence.

• Up to 50% of people with painful diabetic neuropathy report significant sleep disturbance
• Fall rates are 2–3 times higher in people with neuropathy compared to age-matched controls without it
• Depression rates are elevated among people with neuropathy — neuropathy and mental health are deeply interlinked
• Over 50% of people with severe neuropathy report limitations in daily activities

Most Neuropathy Remains Under-treated

A significant portion of people with neuropathy pain don’t receive adequate treatment. Studies sugest that only a fraction of those with potential painful Neuropathy achieve satisfactory pain control with medications.  The most commonly used first-line drugs — gabapentin, pregabalin, duloxetine, and tricyclic antidepressants — provide meaningful relief to roughly 30–50% of patients who try them.

These treatments come at a high cost, not only financially but physically. Some of the side effects attributed to these treatments are (but not limited):

Allergic reactions: hives, facial swelling, difficulty breathing 

Blurred or double vision

Body odor

Dizziness

Drowsiness / sleepiness

Fatigue or weakness

Headache, dizziness, tingling sensations (paresthesia) 

High blood pressure

Memory or thinking problems

Nausea, vomiting, diarrhea, stomach cramps 

Nausea, vomiting, stomach upset

Seizures (reported in multiple sources) 

Severe allergic reactions (rash, swelling of face/lips/tongue/throat)

Severe mood changes or suicidal thoughts

Sexual side effects and bladder changes

Severe skin reactions

Swelling in legs, feet, or hands

Tremor or jerky movements

Unsteady walking or poor coordination

Vision changes

Weight gain

Pregabalin Side Effects: Common, Severe, Long Term

https://www.drugs.com/mtm/levocarnitine.html

Duloxetine Side Effects: Common, Severe, Long Term 

Tricyclic Antidepressants: List, Uses & Side Effects

Is Neuropathy Becoming More Common?

Yes. Neuropathy prevalence is increasing for several reasons: rising diabetes rates, an aging population, improved survival from cancer (meaning more people living with CIPN), and better diagnosis of previously unrecognized conditions like small fiber neuropathy. The treatment market is projected to grow significantly through 2035.

No side effects have been reported with NEURO-FAST.